Share this entry
Pembrolizumab plus chemotherapy effective in squamous cell non-small cell lung cancer
By: News Feed | Last updated: 8th October 2018 | In: Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology
carboplatin, Keytruda, Merck, MSD, nab-paclitaxel, NSCLC, paclitaxel, PD-1, PD-L1, pembrolizumab, squamous cell lung cancer
“Standard first-line therapy for metastatic, squamous NSCLC is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumour cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.”
The Phase III, multi-centre, double-blind controlled KEYNOTE-407 (NCT02775435) study randomised 559 treatment-naïve, untreated metastatic, squamous NSCLC patients in a 1:1 fashion to either receive four cycles of pembrolizumab plus chemotherapy with carboplatin and paclitaxel or nab-paclitaxel followed by maintenance pembrolizumab vs four cycles of placebo plus chemotherapy followed by maintenance placebo. The primary efficacy endpoints were OS and PFS.
At a median follow-up of 7.8 months, the median OS in the pembrolizumab plus chemotherapy arm was 15.9 months (95% CI, 13.2-not reached) vs 11.3 months (95% CI, 9.5-14.8) in the placebo plus chemotherapy arm (HR=0.64; 95% CI, 0.49-0.85; p<0.001), an OS benefit that was consistent regardless of the PD-L1 level expression. The median PFS measured 6.4 months (95% CI, 6.2-8.3) vs 4.8 months (95% CI, 4.3 to 5.7) for the pembrolizumab plus chemotherapy vs placebo plus chemotherapy groups, respectively (HR=0.56; 95% CI, 0.45-0.70; p<0.001).
Grade ≥3 adverse events (AEs) occurred in 69.8% and 68.2% of patients in the pembrolizumab plus chemotherapy-group vs the placebo plus chemotherapy-group, respectively. Treatment discontinuation for AEs occurred in 13.3% and 6.4% of patients, respectively.
Paz-Ares L, et al. N Engl J Med. 2018; doi: 10.1056/NEJMoa1810865.
Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.
YOU MAY ALSO LIKE
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd. – Pembrolizumab plus chemotherapy effective in squamous NSCLC